Roche Secures Second European Nod for Alzheimer's Test

• The pTau217 test is validated for use in both primary and specialist care settings and has already received breakthrough device designation from the U.S. FDA
• Blood tests could accelerate diagnosis and expand access to Alzheimer's treatments like Leqembi and Kisunla, addressing current diagnostic methods that are often costly or invasive
• Approximately 75% of people living with dementia remain undiagnosed, highlighting the significant need for improved diagnostic tools

Summary

Key Development:

Swiss pharmaceutical company Roche has secured CE mark approval for its second Alzheimer's disease blood test, the Elecsys pTau217 test, allowing commercial sale across Europe. The test was developed in collaboration with U.S.-based Eli Lilly.

Product Differentiation:

Unlike Roche's earlier pTau181 test, which primarily rules out Alzheimer's-related amyloid pathology, the new pTau217 test can both confirm and exclude the disease. The diagnostic tool is validated for use in both primary and specialist care settings, broadening its clinical application.

Market Timeline:

The test is expected to launch in CE-marked European markets beginning in July. It has already received breakthrough device designation from the U.S. FDA, indicating potential for future American market entry.

Market Implications:

Blood-based Alzheimer's tests could significantly accelerate diagnosis and expand patient access to recently approved treatments, including Biogen and Eisai's Leqembi and Eli Lilly's Kisunla. Current diagnostic methods—typically involving expensive brain imaging or invasive spinal taps—present barriers to timely treatment.

Critical Context:

An estimated 75% of people living with dementia remain undiagnosed, highlighting substantial unmet medical need and market opportunity for improved diagnostic solutions.

Companies Involved:

• Roche (test developer and manufacturer)
• Eli Lilly (development partner)
• Biogen and Eisai (Alzheimer's treatment providers)

This regulatory approval positions Roche to capture market share in the growing Alzheimer's diagnostics space while potentially supporting broader adoption of next-generation dementia treatments.